Tiago Biachi de Castria, MD, PhD, associate member in the Department of Gastrointestinal Oncology at Moffitt Cancer Center, discusses how precision medicine tools have aided oncologists in treating patients with solid tumors, while reducing overall toxicity.
Precision medicine allows oncologists to have a better understanding of tumor type, behavior, and mechanism resistance, to provide a patient with the right treatment at the right time, says Tiago Biachi de Castria, MD, PhD, associate member in the Department of Gastrointestinal Oncology at Moffitt Cancer Center.
He presented on the topic of “Precision Medicine Developments in Solid Tumors" at our recent Institute for Value-Based Medicine® event in Tampa, Florida.
Transcript
Can you provide an overview of what your topic was about on the significance of precision medicine in solid tumors?
Of course. So, in other words, this is precision oncology; this is a fascinating topic. We're doing a great job, and this is about tumor categorization. So now, we were able to define not only gene sequencing, but we were able to go deeper and analyze tumor RNA expression, protein expression, metabolism, profile of methylation, and microbiomes. By doing that, we have a better sense of what kind of a tumor, tumor behavior, and mechanism resistance. And by doing that, we can offer the right treatment for the right patient at the right time.
What were some of the methods and key metrics used to assess your findings?
I might be biased because I'm a GI [gastrointestinal] medical oncologist, but I used in my presentation a couple examples in colorectal cancer, for example, which is one of my fields that I'm more focused on here at Moffitt. And I used a couple of trials to show how we could translate precision oncology with all these methods in the better treatments and consequently, in better outcomes to our patients. And we discussed about how we can implement precision oncology in more trial designs to try to expedite drug development in oncology.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Bridging Care Gaps With a Systemwide Value-Based Care Strategy
March 29th 2025Mapping care management needs by defining patient populations and then stratifying them according to risk and their needs can help to spur the transformation of a siloed health care system into an integrated system that is able to better provide holistic, value-based care despite the many transitions that continue among hospital, primary, specialty, and community care environments.
Read More
Bridging Education Gaps in Treatment for Scarring Alopecia With Innovative Approaches
March 28th 2025Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, highlights the critical need for comprehensive education on hair loss across diverse hair types, stressing the importance of understanding inflammatory pathways for developing targeted therapies.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More